(ZNTL) |
| 0 (0%) 04-14 05:02 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 8.12 |
| Resistance 1: | 6.95 |
| Pivot price: | 3.11 |
| Support 1: | 3.93 |
| Support 2: | 2.07 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | -1.910 |
| Book Value | 3.130 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -25.2 |
| Return on Equity (ttm) | -49.5 |
Company news
Sun, 12 Apr 2026
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection Milestone - Yahoo Finance
Sun, 12 Apr 2026
A Look At Zentalis Pharmaceuticals (ZNTL) Valuation After Azenosertib Dose Selection News - simplywall.st
Sun, 12 Apr 2026
Is Zentalis (ZNTL) Using Azenosertib’s New Dose To Reframe Its Ovarian Cancer Strategy? - Sahm
Fri, 10 Apr 2026
Guggenheim Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Raises Target Price to $10 - 富途牛牛
Fri, 10 Apr 2026
What's Behind The Surge In Zentalis Stock? - Zentalis Pharmaceuticals (NASDAQ:ZNTL) - Benzinga
Fri, 10 Apr 2026
ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
